NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

May 4 (UPI) -- The U.S. Food & Drug Administration Thursday approved a new drug to treat the most common form of liver cancer, hepatocellular carcinoma.

The drug, regorafenib, is the first and only treatment approved by the FDA in more than a decade to show significant improvement in patients with hepatocellular carcinoma, or HCC.


Regorafenib was shown to extend overall survival by 10.6 months compared to 7.8 months for patients receiving a placebo, resulting in an average improvement in survival of 3.1 months and a 37 percent reduction in the risk of death in patients with HCC.

http://www.upi.com/Health_News/2017/05/04/FDA-approves-new-drug-to-treat-type-of-liver-cancer/9001493927465/